Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. We investigated acalabrutinib plus ob...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Woyach, Jennifer A., Blachly, James S., Rogers, Kerry A., Bhat, Seema A., Jianfar, Mojgan, Lozanski, Gerard, Weiss, David M., Andersen, Barbara L., Gulrajani, Michael, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Munugalavadla, Veerendra, Quah, Cheng, Wang, Min-Hui, Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176161/
https://ncbi.nlm.nih.gov/pubmed/31915195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1130
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados